Chemotherapy-Induced Neutropenia Treatment Market Growth Supported by Key Drivers, Expected to Hit $0.76 Billion by 2029
Grab 20% Off With Code ONLINE20 On Global market Reports – Evaluate Global Trends, Market Risks, and Competitive Intelligence
What Are the Key Growth Indicators and Market Expansion Estimates for the Chemotherapy-Induced Neutropenia Treatment Market Through 2029?
The chemotherapy-induced neutropenia treatment market size has grown strongly in recent years. It will grow from $0.59 billion in 2024 to $0.62 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to increasing cancer incidence rates, rising chemotherapy adoption, growing geriatric population, high hospitalization rates due to infections, and expanding oncology drug pipelines.
The chemotherapy-induced neutropenia treatment market size is expected to see strong growth in the next few years. It will grow to " $0.76 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to rising demand for targeted neutropenia therapies, growing investment in oncology research and development, increasing focus on outpatient care, expanding use of biosimilars, and increasing awareness of infection prevention. Major trends in the forecast period include development of long-acting granulocyte colony-stimulating factor therapy (G-CSF) agents, increasing use of combination therapies, rising preference for home-based care solutions, surge in biosimilar approvals, and integration of digital health monitoring tools.
Get your free report sample today:
Which Core Market Drivers Are Influencing the Development of the Chemotherapy-Induced Neutropenia Treatment Market?
The increasing incidence of cancer is expected to propel the growth of the chemotherapy-induced neutropenia treatment market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The rise in cancer cases is due to the aging population, as older individuals have a higher risk of developing cancer due to accumulated genetic mutations and weakened immune function over time. Chemotherapy-induced neutropenia treatment aids in cancer care by reducing infection risks through immune support, ensuring patients can continue chemotherapy with fewer interruptions. It enhances treatment outcomes by minimizing complications, thereby improving overall patient safety and quality of life. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, the number of cancer cases diagnosed in Australia rose to 160,570 in 2022, an increase of 3,789 cases from 156,781 in 2021. Therefore, the increasing incidence of cancer is driving the growth of the chemotherapy-induced neutropenia treatment market.
How Is the Chemotherapy-Induced Neutropenia Treatment Market Structured Across Its Key Segment Categories?
The chemotherapy-induced neutropenia treatmentmarket covered in this report is segmented –
1) By Type: Antibiotic Therapy; Granulocyte Colony-Stimulating Factor Therapy (G-CSF); Granulocyte Transfusion; Other Types
2) By Route of Administration: Subcutaneous; Intravenous
3) By Indication: Solid Tumors; Hematological Malignancies; Other Indications
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End-User: Hospitals; Specialty Clinics; Homecare Settings
Subsegments:
1) By Antibiotic Therapy: Broad-Spectrum Antibiotics; Narrow-Spectrum Antibiotics; Prophylactic Antibiotics
2) By Granulocyte Colony-Stimulating Factor Therapy (G-CSF): Filgrastim; Pegfilgrastim; Lenograstim
3) By Granulocyte Transfusion: Allogeneic Granulocyte Transfusion; Autologous Granulocyte Transfusion
4) By Other Types: Antifungal Therapy; Stem Cell Therapy; Immunomodulatory Therapy
Which Disruptive Trends Are Reshaping the Competitive Landscape of the Chemotherapy-Induced Neutropenia Treatment Market?
Major companies operating in the chemotherapy-induced neutropenia treatment market are focusing on developing innovative products and getting approvals, such as long-acting formulations to improve patient convenience, reduce dosing frequency, and enhance treatment adherence. Long-acting formulations refer to drug preparations designed to release active ingredients slowly over an extended period, reducing the frequency of administration. For instance, in December 2023, Coherus BioSciences Inc., a US-based biopharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for Udenyca Onbody, a novel, ready-to-use on-body injector. This device containing a long-acting formulation automatically delivers pegfilgrastim approximately 27 hours after chemotherapy, eliminating the need for a next-day injection. Udenyca Onbody enhances patient experience by ensuring timely prophylactic treatment of chemotherapy-induced neutropenia while reducing clinic visits and improving adherence.
Who Are the Principal Market Leaders in the Chemotherapy-Induced Neutropenia Treatment Market?
Major companies operating in the chemotherapy-induced neutropenia treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., GSK plc, Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., Baxter Inteational, Fresenius Kabi, Eisai Co. Ltd., Dr. Reddy's Laboratories Ltd., Exelixis Inc., Biocon Biologics Limited, Coherus BioSciences Inc., G1 Therapeutics, Enzychem Lifesciences Corporation
Get the detailed chemotherapy-induced neutropenia treatment market report today
Which Regions Are Expected to Record the Strongest CAGR in the Chemotherapy-Induced Neutropenia Treatment Market?
North America was the largest region in the chemotherapy-induced neutropenia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced neutropenia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment